KLK3 and cancer: Their results showed that, after a median follow-up of 96 months, there were no significant differences in all-cause, cause specific, metastasis-free, clinical disease-free, or prostate-specific antigen recurrence-free survival rates in 109 black and 167 white men with low-stage cancer treated with surgery or radiation therapy, or in 39 black and 42 white men with high-stage cancer treated with radiotherapy.